Diabetes Mellitus Clinical Trial
— LONGHEADOfficial title:
Long-term Hepatic and Extra-hepatic Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Interferon-free Treatment (LONGHEAD Study)
NCT number | NCT03042520 |
Other study ID # | irb20160082 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 2016 |
Est. completion date | September 2022 |
Primary Objective: To evaluate the long-term outcomes including liver related morbidity, mortality and hepatocellular carcinoma (HCC) development as compared to those of historical control with interferon(IFN)-based treatment. Secondary Objective: 1. To access liver fibrosis progression/regression in CHC patients after sofosbuvir-based treatment. 2. To investigate the long-term outcomes of extrahepatic manifestations of the sofosbuvir-based treated cohort as compared to their pretreatment status.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | September 2022 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Main inclusion criteria: For Sofosbuvir-based therapy observational group: - Patients = 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643) - Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies. Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response: - Patients = 20 of years who had received pegylated interferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response - Patients who have ever participated study will be collected as historical control. Main exclusion criteria: - Patients not qualified by the main inclusion criteria were excluded. For Sofosbuvir-based therapy observational group: - Patients < 20 of years - Patients who are unwilling to participate the current study - Patients who had never participated in parent studies, GS-US-337-0131 (NCT02021656) nor GS-US-334-0115 (NCT02021643) - Patients who had never received at least one dose of sofosbuvir-based therapy in the parent studies. Who IFN-based therapy historical controls: - Patients < 20 of years - Patients who are unwilling to participate the current study - Patients who had never received pegylated interferon plus ribavirin therapy - Patients who did not participate study |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Korea University Ansan Hospital | Ansan | |
Korea, Republic of | Asan Medical Center | Asan | |
Korea, Republic of | Soon Chun Hyang University Hospital Bucheon. | Bucheon | |
Korea, Republic of | Dong-A University Hospital | Busan | |
Korea, Republic of | Inje University Busan Paik Hospital | Busan | |
Korea, Republic of | Kyungpook National University Hospital | Daegu | |
Korea, Republic of | Gachon University Gil Hospital | Incheon | |
Korea, Republic of | Pusan National University Hospital | Pusan | |
Korea, Republic of | Gangnam Severance Hospital | Seoul | |
Korea, Republic of | Korea University Guro Hospital | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Bundang Hosptial | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | Severance Hospital | Seoul | |
Taiwan | Changhua Christian Hospital | Changhua | |
Taiwan | Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | Kaoshiung Medical University Hospital | Kaohsiung City | |
Taiwan | Keelung Chang Gung Memorial Hospital | Keelung | |
Taiwan | China Medical University | Taichung | |
Taiwan | Chi Mei Liouying Hospital | Tainan | |
Taiwan | MacKay Memorial Hospital | Taipei | |
Taiwan | National Cheng Kung University Hospital | Taipei | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
Taiwan | Linkou Chang Gung Memorial Hospital | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Kaohsiung Medical University Chung-Ho Memorial Hospital | Asan Medical Center, Chang Gung Memorial Hospital, Changhua Christian Hospital, Chi Mei Medical Hospital, China Medical University, China, Dong-A University Hospital, Gachon University Gil Medical Center, Gangnam Severance Hospital, Inje University, Korea University, Korea University Guro Hospital, Kyungpook National University Hospital, Mackay Memorial Hospital, National Cheng-Kung University Hospital, National Taiwan University Hospital, Pusan National University Hospital, Samsung Medical Center, Seoul National University Bundang Hospital, Seoul National University Hospital, Seoul St. Mary's Hospital, Severance Hospital, Soon Chun Hyang University, Taipei Veterans General Hospital, Taiwan |
Korea, Republic of, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with liver-related morbidity development during 5-year follow-up period after sofosbuvir-based treatment | Number of participants with liver-related morbidity during 5-year follow-up period after sofosbuvir-based treatment, including liver fibrosis progression and decompensation | 6 years | |
Primary | Number of participants with liver-related mortality development during 5-year follow-up period after sofosbuvir-based treatment | Number of participants with liver-related mortality assessed by death due to HCC and/or liver decompensation | 6 years | |
Primary | Number of participants with hepatocellular carcinoma (HCC) development during 5-year follow-up period after sofosbuvir-based treatment | Number of participants with HCC assessed by histocytology or positive dynamic image plus alpha fetoprotein (AFP) > 400 ng/ml | 6 years | |
Secondary | Life quality | The change of short form(SF)-36 from baseline | 6 years | |
Secondary | Cryoglobulinemia | Change of proportion of participants with cryoglobulinemia from baseline cryoglobulinemia from baseline) | 6 years | |
Secondary | Diabetes mellitus (DM) | Number of participants without DM develop DM assessed by Ac sugar > 126 g/ml | 6 years | |
Secondary | Insulin resistance | Change of homeostatic model assessment (HOMA-IR), assessed by Glucose x insulin/22.5 from baseline | 6 years | |
Secondary | Lipid profiles | Change of the serum profile of lipids including triglyceride(TG), cholesterol(Chol), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) from baseline | 6 years | |
Secondary | Renal disease | the change of the estimated glomerular filtration rate (eGFR) from baseline | 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |